Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2024-01-04 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Receives Tentative Approval from U.S. FDA for Dapagliflozin and Saxagliptin Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for an Abbreviated New Drug Application. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product marketing plans, not a financial report or detailed filing. The document length is 4419 characters, which is relatively short and consistent with a press release or regulatory announcement. There are no financial statements, management discussion, or detailed report data. It is not an earnings release, annual report, or interim report. It is a regulatory disclosure under Listing Regulations, which fits best under Regulatory Filings (RNS).
2024-01-04 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer. It is addressed to stock exchanges and signed by the company secretary. The document is short (2889 characters) and is a regulatory compliance communication rather than a financial report or announcement of voting results, management changes, or capital changes. It does not contain financial data or report results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2024-01-04 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer, addressed to stock exchanges. The document is short (2817 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial data or management discussion, nor is it an announcement of voting results or capital changes. It is a regulatory filing related to share certificate compliance under SEBI regulations, fitting the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory compliance documents.
2024-01-04 English
Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or comprehensive report data. It is a regulatory disclosure about a significant corporate event (FDA approval) rather than a financial report or management discussion. The length is 4319 characters, which is relatively short and typical for a press release or regulatory announcement. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and disclosures that do not fit other specific categories.
2023-12-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or comprehensive report content. It is a regulatory disclosure about a significant corporate event (FDA approval) rather than a financial report or management discussion. The length is 4316 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-27 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about the closure of the trading window for designated persons due to insider trading regulations. It references SEBI regulations and the upcoming announcement of quarterly financial results for the period ending December 31, 2023. The document does not contain any financial data, results, or detailed report content. It is a regulatory announcement related to trading restrictions ahead of financial results disclosure. The document length is short (2043 characters) and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a compliance-related announcement.
2023-12-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.